Drug Database
PO

polio vaccine (Polymilex)

✓ Approved

Nanolek, LLC · 疫苗 · 疫苗

什么是 polio vaccine?

polio vaccine 是一种疫苗,由Nanolek, LLC研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名Polymilex
公司Nanolek, LLC
药物类别疫苗, 大分子
给药途径Unknown
状态Approved

治疗适应症

polio vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresPolio immunisation✓ Approved

相关研究文献

PubMedArchives of public health = Archives belges de sante publique2026-11-19

Progress toward poliomyelitis eradication - January 2023-December 2024.

Whitmire Hailey H, Wadood M Zubair MZ, Storm Ina G IG, Bjork Adam A et al.

Since the establishment of the Global Polio Eradication Initiative (GPEI) in 1988, wild poliovirus type 1 (WPV1) remains endemic in only Afghanistan and Pakistan. However, outbreaks of paralytic polio caused by circulating vaccine-derived polioviruses (cVDPVs) emerge in areas with low vaccination coverage and continue to challenge polio eradication goals. As the Global Polio Eradication Initiative extends its eradication target to 2029, understanding the epidemiologic, surveillance, and operational factors associated with persistent transmission is critical for informing policy decisions and targeting limited resources. This report describes global polio immunization efforts, surveillance activities, and epidemiology during January 2023-December 2024. Surveillance and virologic data were obtained from the World Health Organization's (WHO) global Polio Information System (POLIS), and immunization coverage estimates were sourced from WHO's Immunization Dashboard, which incorporates administrative and survey-based data from WHO and UNICEF. A cVDPV outbreak was defined using standardized acute flaccid paralysis (AFP) and environmental surveillance criteria; analyses were conducted in R (version 4.4.1). Afghanistan and Pakistan reported 99 WPV1 cases in 10 provinces in 2024, compared with 12 cases in 3 provinces in 2023. cVDPV cases decreased 12% from 529 in 2023 to 464 in 2024. However, cVDPV detections from AFP and environmental surveillance expanded geographically, with detections in 40 countries in Africa, Southeast Asia, the Middle East and Europe in 2024, including 14 countries with no detections in 2023. The resurgence of WPV1 in polio-free regions in Afghanistan and Pakistan and the spread of cVDPVs challenge global polio eradication. Achieving global polio eradication will require reaching persistently missed children in remote and insecure areas, strengthening vaccination and surveillance systems, and reinforcing accountability to improve campaign quality. The geographic expansion of cVDPV type 2 (cVDPV2) underscores the need for rapid detection, expanded nOPV2 use in areas with prolonged transmission, and sustained partner engagement and strategic resource allocation amid declining global health funding.

PMID 43053198
阅读全文 →
PubMedWellcome open research2026-11-19

Did the emergence of the Omicron variant impact the COVID-19 vaccine acceptance in the Arab world? A Twitter-based sentiment analysis.

Dimashkieh Chehab Nada N

Low vaccine acceptance constitutes a major obstacle for achieving herd immunity against coronavirus disease 2019 (COVID-19). Data on COVID-19 show a significant rise in the number of cumulative cases in Arab countries where vaccine uptake is lower than the uptake at the global level for the 2021-2022 period. The aim of this study is to analyze sentiments related to vaccine acceptance before and after the emergence of the COVID-19 Omicron variant in the Arab-speaking world. Tweets were collected before and after the Omicron emergence period in the Arab-speaking world using Python-enabled CAMeL Tools (Arabic Natural Language Processing toolkit) libraries. A sentiment analysis on COVID-19 vaccines using Arabic hashtags and a sentiment analysis by city were conducted. Two data sets pre-Omicron and post-Omicron tweets exhibited a difference in sentiments marking a shift towards less negativity and more neutrality. Sentiments by city showed most tweets in both periods coming from Riyadh and Jeddah in Saudi-Arabia, and from Salt in Jordan. Despite the limitations of the study, the change in sentiments detected by the study may suggest more vaccine acceptance which raises some hope and perhaps a higher vaccine uptake in the future. The sentiments by city findings may help in the design of future research.

PMID 43053887
阅读全文 →
PubMedNPJ vaccines2026-11-19

SARS-CoV-2 RBD fusion ameliorates enhanced disease induced by RSV G CCD mRNA vaccine in BALB/c mice.

Sun Yufang Y, Xie Ying Y, Liu Lian L, Yang Huijie H et al.

Respiratory syncytial virus (RSV) is a primary pathogen responsible for lower respiratory tract infections in both infants and the elderly. However, vaccine development has been consistently hampered by the risk of vaccine-enhanced disease (VED), while the role of the RSV attachment (G) glycoprotein has long been overlooked. Using an mRNA vaccine platform, this study systematically evaluated the roles of two critical RSV G protein domains-the central conserved domain (CCD) and the mucin-like domains-in mediating immune protection and VED. Results indicate that the mucin-like domains confer no protection and induce marked VED. Surprisingly, although CCD immunization elicits potent humoral immunity and significantly reduces viral load, it also induces Th2-biased responses and exacerbates pulmonary inflammation following RSV challenge. However, fusion of CCD with the receptor-binding domain (RBD) of SARS-CoV-2 in an mRNA vaccine (CCD + RBD) successfully redirected the Th2-biased immune responses toward a balanced Th1/Th2 profile, while significantly attenuating CCD-induced immunopathology. CD8⁺ T-cell depletion and adoptive-transfer experiments further supported a contribution of RBD-responsive CD8⁺ T cells to the reduction in pathology. These findings provide proof of concept that heterologous antigen fusion can reshape CCD-associated immunopathology in a BALB/c RSV challenge model.

PMID 43052326
阅读全文 →
PubMedNPJ vaccines2026-11-19

Efficacy, safety, and biodistribution of intranasally delivered adenoviral COVID-19 vaccine in hamsters.

Laham-Karam N N, Mäkinen P P, Koivulehto E E, Gurzeler E E et al.

Coronavirus disease 2019 (COVID-19) continues to cause outbreaks around the world despite the vast COVID-19 vaccination programs. Thus, it is important to continue developing better vaccines to protect vulnerable populations. Here, we studied the efficacy, safety, persistence and biodistribution of an adenovirus-based COVID-19 vaccine delivered intranasally. Our results confirmed that mucosal delivery leads to effective protection against infection in hamsters. A comparative study of different adenoviral vectors demonstrated that specifically Ad5-S-3M, expressing the SARS-CoV-2 spike glycoprotein ectodomain with inclusion of three common receptor binding domain mutations, induced a robust humoral immune response and effectively protected hamsters from SARS-CoV-2 infection. In addition, longitudinal analysis of vaccinated hamsters' tissues demonstrated durable vaccine transgene expression and persistent vector DNA in the nasal turbinates. This persistence may be beneficial in increasing the duration of immunity. Expression of the S-3M did not cause any aberrant changes in the hamster tissues and resulted in very few changes in cellular mRNA expression in target tissues. Safety and biodistribution assessment demonstrated restricted non-target tissue distribution of intranasally delivered vector and no significant changes in clinical blood chemistry, underlining the safety of the vaccine. These results further support that intranasal delivery is a promising approach for mucosal vaccine administration against respiratory infection pathogens and extend our knowledge of Adeno-vector persistence.

PMID 43052363
阅读全文 →
PubMedNPJ vaccines2026-11-19

Influenza neuraminidase as adjuvanted protein or mRNA vaccine protects mice against influenza A and B virus challenge.

Portela Catani João Paulo JP, Smet Anouk A, Ysenbaert Tine T, Amelinck Laura L et al.

Neuraminidase (NA) is an underutilized influenza vaccine antigen despite its recognized contribution to protective immunity. Here, we compared the immunogenicity and protective potential of multiple NA antigens delivered as an adjuvanted recombinant tetrameric protein or as mRNA-LNP encoding full-length NA in naïve mice. Both vaccine types induced robust neuraminidase-inhibiting (NAI) antibody responses and conferred protection to mice challenged with antigenically homologous influenza A or B viruses. However, only immunization with NA-encoding mRNA-LNP protected against challenge with a heterologous HxN2 virus, whereas immunization with recombinant NA was associated with earlier onset of weight loss following heterologous HxN2 virus challenge. Passive transfer of immune serum revealed that protection induced by mRNA immunization can be transferred by serum, and that early onset of weight loss is not induced by recombinant NA-derived sera; on the contrary, partial protection is achieved. Finally, NAI assays against a panel of antigenically distinct HxN2 viruses showed similar breadth of inhibition.

PMID 43052397
阅读全文 →
PubMedNPJ vaccines2026-11-19

Biosynthesis of a nanoscale Vibrio cholerae conjugate vaccine elicits potent immunity through size and receptor effects.

Wang Kangfeng K, Huang Jing J, Li Juntao J, Li Zhenshi Z et al.

Cholera, caused by Vibrio cholerae, remains a significant global health threat, with the O1 serotype being the predominant cause of recent global outbreaks. Although conjugate vaccines against V. cholerae have been developed via chemical methods, the feasibility of applying novel biosynthetic approaches remains uncertain due to the special structure of its O-polysaccharide, which should be recognized by oligosaccharyltransferases. Here, we successfully established an oligosaccharyltransferase PglL-based glycosylation system in an engineered V. cholerae strain to biosynthesize a nanoscale conjugate vaccine, NP-OPSVc(I). The carrier NP was designed by fusing the cholera toxin B subunit (CTB) with a trimer-forming protein (Tri), which could self‑assemble into a nanoparticle during expression. The resulting glycoprotein exhibited high purity, stability, and retained GM1-binding capacity. We found that the size of NP-OPSVc(I) and its GM1 receptor targeting both contribute to a potent humoral immune response, while its efficient delivery is additionally associated with the induction of intestinal mucosal immunity. In mouse models, the NP-OPSVc(I) demonstrated a favorable safety profile and elicited substantially stronger systemic and mucosal immune responses than conventional conjugates, providing great protection against lethal V. cholerae challenge even at a 10‑fold lower dose without requiring an adjuvant. Furthermore, the immune responses were confirmed in non-human primates, supporting its potential for clinical translation. This work not only developed a novel highly effective candidate vaccine against V. cholerae but also significantly expanded the application scope of the PglL-based platform technology, establishing it as a versatile and broadly applicable enzymatic toolkit for vaccine development.

PMID 43052362
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多polio vaccine